This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

B. Lynne Parshall, Director astatine Cytokinetics, Incorporated (NASDAQ:CYTK), reported the merchantability of 5,000 shares successful an open-market transaction valued astatine ~$323,650 connected November 19, 2025; nonstop ownership pursuing the merchantability stands astatine 22,933 shares, according to the SEC Form 4 filing.

Transaction worth based connected SEC Form 4 reported terms ($64.73); post-transaction worth based connected Nov. 19, 2025 marketplace adjacent ($64.79).

• How important was this merchantability comparative to B. Lynne Parshall's remaining nonstop holdings?
  The disposition represented 17.9% of nonstop ownership instantly anterior to the transaction, with post-sale holdings astatine 22,933 shares.

• How does this transaction comparison to the insider's humanities selling pattern?
  The merchantability of 5,000 shares matches the humanities median merchantability size for B. Lynne Parshall, though the percent of holdings sold per transaction has accrued arsenic the stock basal has declined, reflecting reduced disposable capableness alternatively than accrued commercialized size.

• What is the existent worth of the insider's remaining nonstop position?
  Based connected the November 19, 2025 closing terms of $64.79, the post-transaction nonstop holding is valued astatine astir $1.49 million.

• How does the transaction worth subordinate to Cytokinetics, Incorporated's one-year banal performance?
  The ~$323,650 merchantability occurred with shares priced astatine $64.73, pursuing a 27.36% full instrumentality for the banal implicit the preceding 12 months arsenic of the transaction date.

Note: 1-year show calculated utilizing November 19th, 2025 arsenic the notation date.

• Cytokinetics develops tiny molecule cause candidates targeting musculus function, with a pipeline including omecamtiv mecarbil (cardiac myosin activator), reldesemtiv (skeletal musculus troponin activator), aficamten (cardiac myosin inhibitor), and different early-stage assets.

• The institution operates a late-stage biopharmaceutical exemplary focused connected cause discovery, objective development, and aboriginal commercialization, generating gross chiefly from strategical alliances and milestone payments.

• It targets healthcare providers and patients affected by bosom failure, neuromuscular, and uncommon musculus diseases, with a absorption connected the U.S. and planetary biopharmaceutical markets.